Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease

Keywords

Dopaminergic, Neuroscience, Parkinson's disease, Neurotrophic factors, Genetically engineered

References

• Morphological and neurochemical features of cultured primary skin fibroblasts of fischer 344 rats following striatal implantation正寛 富永, 英成 具, 武 岩崎 — 1992
• Neurotrophic factors: from molecule to man.С. К. Крепышева, S I Zhuravlev — 1994
• Brain-derived neurotrophic factor works coordinately with partner molecules to initiate tyrosine hydroxylase expression in striatal neurons.Gavin Newby, Paul Skirrow — 1995
• The rat brain in stereotaxic coordinates: Authors: George Paxinos & Charles Watson Academic Press Australia, 1982 Softback, 154 pages (including 71 plates), 35.00 Aust $Miklós Palkovits — 1983
• Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transectionJK Morse, SJ Wiegand, Karen E. Anderson — 1993
• The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents.Gerald Cohen, Richard E. Heikkila, With the technical assistance of Dana MacNamee — 1974
• Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brainBeat Knüsel, KD Beck, J.R. Winslow — 1992
• The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systemsC R Gerfen, Miles Herkenham, J. Thibault — 1987
• Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat.David M. Frim, Tara A. Uhler, Wendy R. Galpern — 1994
• BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigraCarolyn Hyman, Magdalena Hofer, Yves‐Alain Barde — 1991
• D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.Charles R. Gerfen, Thomas M. Engber, Lawrence C. Mahan — 1990
• Neurotransmitters and neuromodulators in the basal ganglia.Ann M. Graybiel — 1990
• The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.Ronald M. Lindsay, C. Anthony Altar, Jesse M. Cedarbaum — 1993
• New insights into the cause of Parkinson's diseasePeter Jenner, Anthony H.V. Schapira, C. D. Marsden — 1992
• Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve sectionMichael Sendtner, Bettina Holtmann, R. Kolbeck — 1992
• Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3.Beat Knüsel, John Winslow, Arnon Rosenthal — 1991
• Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence.Serge Przedborski, Marc Levivier, Vladimir Kostić — 1991
• The oxidant stress hypothesis in Parkinson's disease: Evidence supporting itS Fahn, Gerald Cohen — 1992
• Molecular cloning of a human gene that is a member of the nerve growth factor family.Kevin R. Jones, Louis F. Reichardt — 1990
• Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection.Paul A. Lapchak, Kevin D. Beck, Dalia M. Araujo — 1993

Cited by

• Implanted BDNF-producing fibroblasts prevent neurotoxin-induced serotonergic denervation in the rat striatum.Janet Zarem — 2000
• Gene therapy in Parkinson’s diseaseO. Eberhardt, Jörg B. Schulz — 2004
• Changes in cytokines and neurotrophins in Parkinson's disease.Toshiharu Nagatsu, Makio Mogi, Hiroshi Ichinose — 2000
• PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's diseaseNaomi P. Visanji, Antonia Orsi, Tom H. Johnston — 2008
• Phenotype, compartmental organization and differential vulnerability of nigral dopaminergic neurons.Tomás González‐Hernández, Domingo Afonso‐Oramas, Ignacio Cruz‐Muros — 2009
• Application of ex vivo gene therapy in the treatment of Parkinson's disease.Heather K. Raymon, Silke Thode, Fred H. Gage — 1997
• Encapsulated neural transplants.Jack Tseng, Patrick Aebischer — 2000
• Modulation of excessive neuronal activity by fibroblasts: Potential use in treatment of Parkinson's diseaseJ. P. M. Finberg, Zoya Gluzman, Michal Reshef — 2010
• Molecular and Cellular Characterization of Dopamine Neuron Stimulating PeptidesKristen A. Kelps — 2013
• Approaches in the treatment of Parkinson's disease: A focus on stem cell-based therapiesTareq Al-Maqtari — 2012
• Experimental models of Parkinson's disease: insights from many models.R J Tolwani, Michael W. Jakowec, G M Petzinger — 1999
• Neurotrophic factors and neurodegenerative diseases: a delivery issue.Barbara Ruozi, Daniela Belletti, Lucia Bondioli — 2012
• Somatic gene therapy in animal models of Parkinson's disease.M. Bauer, Marius Ueffing, Thomas Meitinger — 1999
• Interventions that Improve Body and Brain Bioenergetics for Parkinson's Disease Risk Reduction and TherapyMark P. Mattson — 2014
• Gene Therapy for Parkinson’s DiseaseJos� Segovia — 2002
• Encapsulated cell implants as a novel treatment for Parkinson's disease.Jack Tseng, Patrick Aebischer — 2001
• Infarctus cérébral et plasticité : focus sur le BDNFYannick Béjot — 2011
• Role of Exercise and GDNF in an Animal Model of Parkinson's Disease: Implications for NeuroprotectionAnnie Cohen — 2006
• Birth, life and death of dopaminergic neurons in the substantia nigra.Giuseppe Di Giovanni, Vincenzo Di Matteo, Ennio Esposito — 2009
• Increased Survival of Dopaminergic Neurons in Striatal Grafts of Fetal Ventral Mesencephalic Cells Exposed to Neurotrophin-3 or Glial Cell Line-Derived Neurotrophic FactorMònica Espejo, Blanca Cutillas, Ernest Arenas — 2000

Related papers

• GDNF family signalling in exocrine tissues: distinct roles for GDNF and neurturin in parasympathetic neuron development.Jari Rossi, Matti S. Airaksinen — 2002
• Differential effects of glial cell line‐derived neurotrophic factor and neurturin in RET/GFRα1‐expressing cellsRebecca Hui Kwan Lee, Wai Lap Wong, Chin Ho Chan — 2006
• Persephin, a novel neurotrophic factor related to GDNF and neurturin.Jeffrey Milbrandt, Frédéric J. de Sauvage, Timothy J. Fahrner — 1998
• The GDNF family ligands and receptors - implications for neural development.Robert H. Baloh, Hideki Enomoto, Eugene M. Johnson — 2000
• CNS glia are targets for GDNF and neurturinBarbara Franke, Maciej Figiel, Jürgen Engele — 1998
• Developmental changes in neurite outgrowth responses of dorsal root and sympathetic ganglia to GDNF, neurturin, and arteminHuiying Yan, Don Newgreen, Heather M. Young — 2003
• Capacity of Neurotrophic Factors of the GDNF Family in Supporting the Survival of Dopaminergic Neurons in the Central Nervous System of the Aging MouseTavia Goodison — 2013
• GDNF expression in human skeletal muscleHidenori Suzuki, Asako Hase, Yuhei Miyata — 1998
• GDNF family receptor complexes are emerging drug targets.Maxim M. Bespalov, Märt Saarma — 2007